Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant

被引:6
|
作者
Reich-Slotky, Ronit [1 ]
Al-Mulla, Naima [2 ]
Hafez, Rania [3 ]
Segovia-Gomez, Javier [4 ]
Goel, Ruchika [5 ,6 ]
Mayer, Sebastian [7 ]
Phillips, Adrienne [7 ]
Shore, Tsiporah B. [7 ]
Hsu Jing-Mei [7 ]
Hsu, Yen-Michael Sheng [7 ]
Vasovic, Ljiljana V. [7 ]
Cushing, Melissa M. [7 ]
Gergis, Usama [7 ]
机构
[1] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[2] Hamad Med Corp, Doha, Qatar
[3] Assiut Univ, Sch Med, Assiute, Egypt
[4] Cent Mil Hosp Bogota, Bogota, Colombia
[5] Johns Hopkins Univ, Dept Pathol, Div Transfus Med, Baltimore, MD USA
[6] Simmons Canc Inst, SIU Sch Med, Springfield, IL USA
[7] Weill Cornell Med Coll, Pathol, New York Presbyterian Hosp, New York, NY USA
关键词
PGF; delayed hematopoietic recovery; poor graft function; CORD BLOOD TRANSPLANTATION; BONE-MARROW; ABO INCOMPATIBILITY; PLATELET RECOVERY; HOST-DISEASE; DONOR; HLA; IMPACT; OUTCOMES; APLASIA;
D O I
10.1080/10428194.2020.1789622
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PGF implies persistent cytopenia in the presence of predominant donor chimerism. We examined contributors to PGF in 104 HCT recipients who survived >= 100 days without relapse or major complications. Surrogate parameters for PGF were: Hg <10 g/dl, RBC transfusion dependence, platelet count <20 x 10(9)/L or ANC < 0.5 x 10(9)/L. All patients received T cell depletion with alemtuzumab or ATG. The 2-year OS and PFS probabilities were 66%, 95%CI (56 - 75%) and 51%, 95%CI (41-60%) respectively. Fifty-four patients (52%) met one or more PGF criteria. There was significant association between major ABO incompatibility and platelet <20 x 109/L (OR = 4.7, 95%CI 1.05-21.26,p = .043), acute GVHD and Hg <10 g/dl (OR 3.7, 95%CI 1.4-9.6,p = .005) and CMV viremia and ANC < 0.5 x 10(9)/L (OR 3.0, 95% CI 1.0, 8.7,p = .043). NRM was significantly higher in the PGF group compared to patients with adequate graft function (45.5% vs 16.7%,p = .014).
引用
下载
收藏
页码:2894 / 2899
页数:6
相关论文
共 50 条
  • [41] Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation
    Chen, Juan
    Wang, Hongtao
    Zhou, Jiaxi
    Feng, Sizhou
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [42] Dysregulated T Cell Response in Bone Marrow Immune Micro-Environment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
    Wang, Yu-tong
    Kong, Yuan
    Song, Yang
    Jiang, Zheng-Fan
    Huang, Xiao-jun
    BLOOD, 2015, 126 (23)
  • [43] Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia
    Savani, BN
    Rezvani, K
    Mielke, S
    Montero, A
    Kurlander, R
    Carter, CS
    Leitman, S
    Read, EJ
    Childs, R
    Barrett, AJ
    BLOOD, 2006, 107 (04) : 1688 - 1695
  • [44] Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation
    Almyroudis, N. G.
    Jakubowski, A.
    Jaffe, D.
    Sepkowitz, K.
    Pamer, E.
    O'Reilly, R. J.
    Papanicolaou, G. A.
    TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (04) : 286 - 294
  • [45] Deferasirox restores hematopoiesis in poor graft patients after allogeneic hematopoietic stem cell transplantation
    Visani, G.
    Guiducci, B.
    Loscocco, F.
    Clissa, C.
    Gabucci, E.
    Giardini, C.
    Isidori, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S282 - S282
  • [46] Chimerism analysis of langerhans cells early after T cell depleted allogeneic hematopoietic stem cell transplantation
    Schmitt, Tinto
    Schneiker, Kerstin
    Konur, Abdo
    Hadian, Ali
    Bender, Klaus
    Stebut, Esthervon
    Kolbe, Karin
    Huber, Christoph
    Herr, Wolfgang
    Meyer, Ralf G.
    BLOOD, 2007, 110 (11) : 954A - 954A
  • [47] Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation
    Al-Ramahi, Joe S.
    Shahzad, Moazzam
    Nguyen, Andrea
    Li, Kevin
    Amin, Muhammad Kashif
    Ahmed, Nausheen
    Lutfi, Forat
    Dejarnette, Shaun
    Chaudhary, Sibgha Gull
    Bansal, Rajat
    Abdelhakim, Haitham
    Shune, Leyla
    Abdallah, Al-Ola
    Singh, Anurag K.
    Abhyankar, Sunil H.
    Mcguirk, Joseph P.
    Mushtaq, Muhammad Umair
    BONE MARROW TRANSPLANTATION, 2024, 59 (01) : 134 - 137
  • [48] Clinical and Immunological Factors Associated with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis Patients
    Kwag, Daehun
    Min, Gi-June
    Park, Sung-Soo
    Park, Silvia
    Yoon, Jae-Ho
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Kim, Hee-Je
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Jong-Wook
    Lee, Sung-Eun
    BLOOD, 2023, 142
  • [49] Hematopoietic recovery with manageable complications after stem cell boost with immunomagnetic selection in the therapy of allogeneic poor graft function
    Fraczkiewicz, J.
    Majcherek, M.
    Szeremet, A.
    Ryczan-Krawczuk, R.
    Rybka, B.
    Wrobel, T.
    Czyz, A.
    Ussowicz, M.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 407 - 407
  • [50] CD34+-selected stem cell boost without further conditioning for poor graft function after allogeneic hematopoietic stem cell transplantation
    Klyuchnikov, E.
    Elcheikh, J.
    Blaise, D.
    Bacher, U.
    Ayuk, F.
    Lioznov, M.
    Alchalby, H.
    Zander, A. R.
    Kroeger, N.
    ONKOLOGIE, 2011, 34 : 280 - 281